Checkpoint / AEs / The New England Journal / Dendreon Corporation / Merck / Genentech USA Inc. / Bristol-Myers Squibb / /
Country
United States / /
Event
FDA Phase / /
IndustryTerm
pharmaceutical development / hybridoma technology / cancer therapy / cancer therapies / treatment of NHL and chronic lymphocytic leukemia / concurrent / treatment of melanoma / printing / /
MedicalCondition
inflammatory response / ovarian cancer / multiple myeloma / lymphoma / colorectal cancer / chronic autoimmune inflammation / chronic lymphocytic leukemia / killed infectious agents / follicular lymphoma / dermatitis / advanced / metastatic solid tumors / Dranoff G. Cancer / metastatic solid tumors / solid tumors / therapeutic cancer / Advanced melanoma / small cell lung cancer / colitis / castrationresistant prostate cancer / melanoma / fatigue / Unresectable stage III/IV melanoma / pulmonary edema / non-small cell lung cancer / diarrhea / Relapsed/refractory hematologic malignancy Monotherapy NCT01358721 / renal cell carcinoma / metastatic / castration-resistant prostate cancer / Advanced/metastatic squamous cell non-small cell lung cancer / pruritus / tumor / III/IV malignant melanoma / Introduction Cancer / Unresectable melanoma / Cancer / tumors / disease / NSCLC / follicular lymphoma patients / hypothyroidism / T cell Dendritic cell Lymph node Cancer / hepatocellular carcinoma / metastatic renal cell carcinoma / advanced solid tumors / chronic viral hepatitis Monotherapy NCT01472081 / hematologic malignancies / MHC Tumor / advanced cancer / TCR MHC Tumor / Cancer I / renal cell carcinoma Monotherapy NCT01658878 / Response Evaluation Criteria In Solid Tumors / nonsmall cell lung cancer / rapid and deep tumor / positive breast cancer / stable disease / advanced / treatment-refractory solid tumors / infectious diseases / infection / measurable tumor / different cancer / rash / established cancer / Metastatic melanoma / /
MedicalTreatment
radiation therapy / immunotherapies / active immunotherapy / passive immunotherapy / vaccination / chemotherapy / Immunotherapy / cancer therapy / immunosuppression / passive immunotherapies / cancer therapies / active immunotherapies / /
Organization
World Health Organization / Annual Society of Hematology / American Society of Clinical Oncology / NS NS / FDA / /
Priming phase Effector phase MHC